

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for CV900001L

AAV2-CMV-GFP Control Particle


Product data:

Product Type:	AAV Control Particles
Description:	AAV2 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
Reporter:	GFP
Promoter:	CMV
Serotype:	AAV-2
Purification Method:	lodixanol
Storage Buffer:	PBS with 0.001% Pluronic F68
Validation:	To validate the quality of our AAV control particles, we have developed the following procedure:1. AAV genome titer is determined by qPCR.2. AAV transduction efficiency is analyzed by in vitro transduction in HEK293T.
Stability:	AAV is stable for 1 year when stored at -80°C (long-term storage) or 2-3 weeks when stored at -20°C (short-term storage). Thaw the vial of AAV on ice prior to use and keep it on ice during the experiment. Thawed AAV can be stored at 4°C for 1-2 weeks. Whenever possible, particles should be aliquoted into single use portions to avoid repeated freeze/thaw cycles. Please aliquot at least 10ul per tube and use low protein binding tubes to avoid loss of virus.



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2025 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US **GRIGENE** AAV2-CMV-GFP Control Particle – CV900001L

Product images:



In-vitro transduction efficiency of HEK293T cell line with AAV-2.

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2025 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US